Vanda Pharmaceuticals Inc. (VNDA)

12.99
NASDAQ : Health Technology
Prev Close 13.31
Day Low/High 12.72 / 13.52
52 Wk Low/High 13.00 / 33.44
Avg Volume 720.00K
Exchange NASDAQ
Shares Outstanding 52.96M
Market Cap 704.95M
EPS 0.50
P/E Ratio 32.46
Div & Yield N.A. (N.A)

Biotech Stock Mailbag: Avanir Pharma

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Biotech Stock Mailbag - 2Q Updates

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Biotech Stock Mailbag: Amarin Pharma

Biotech Stock Mailbag: Amarin Pharma

Biotech columnist Adam Feuerstein answers readers' questions and concerns about healthcare and drug-related stocks.

Vanda Schizophrenia Drug Gets Rotten Review

Vanda's Fanapt is treated roughly in the new psychiatrists' 'bible', further hurting the drug's launch efforts.

Biotech Calendar: Key Dates for May

Here's a list of May's potentially stock-moving biotech events.

Biotech Stock Mailbag: Labopharm

Our biotech watchdog answers readers' questions and tweets about drug- and health care-related stocks.

Biotech Earnings: Large-Cap Preview

Biotech Earnings: Large-Cap Preview

Biotech's first-quarter earnings season kicks off next week. Here are earnings summaries for nine revenue-generating biotech stocks.

Biotech Stock Mailbag: Generex, Part II

Biotech columnist Feuerstein answers readers' questions about Generex, Cell Therapeutics and other stocks.

Call-Selling in Vanda Pharma

Call-Selling in Vanda Pharma

Expecting limited upside, a call seller boosts volume in Vanda Pharmaceuticals.

Biotech's 2009 Movers & Shakers: BioBuzz

A look back at 2009's best- and worst-performing bitoech stocks.

Nasdaq 2009 Winners & Losers

Nasdaq 2009 Winners & Losers

Diedrich Coffee is up 9,580%, RHI Entertainment lands at the bottom, down 96%.

Vanda's Fanapt Deal Just Okay: BioBuzz

Vanda's Fanapt Deal Just Okay: BioBuzz

Bulls were hoping for a Vanda takeover.

Novartis to Market Vanda's Fanapt Drug

Novartis to Market Vanda's Fanapt Drug

Vanda Pharmaceuticals entered into an exclusive license agreement with Novartis to commercialize and develop schizophrenia drug Fanapt in the U.S. and Canada.

Novartis, Vanda In Drug Deal Worth Up To $265M

Novartis, Vanda In Drug Deal Worth Up To $265M

Novartis to pay Vanda up to $465 million for rights to sell schizophrenia drug in US, Canada

Bullish Case for Vanda Loses Steam

Bullish Case for Vanda Loses Steam

Vanda's chances of getting acquired seem to be drying up, according to two analysts.

Biotech Stock Mailbag: Genta Takes Another Stab

Biotech Stock Mailbag: Genta Takes Another Stab

Readers weigh in on Genta, Opexa, Osiris, Vivus and Antigenics.

Weighing Arena's Obesity Drug: Biotech Mailbag

Readers weigh in on Arena Pharmaceuticals' obesity drug, Affymax's stock, and Cell Therapeutics' pixantrone.

Vanda, Oculus, Sequenom: Biotech Notebook

Vanda Pharmaceuticals can't find a buyout partner; Oculus Innovative Sciences backs off drug claims; Sequenom walks back expectations for its Downs syndrome gene test.

Stock Search: Bank of America, General Electric

Stock Search: Bank of America, General Electric

For the fourth day in a row, Bank of America remains atop TheStreet.com's stock-search list. New entries to the list include Cell Therapeutics, Hemispherx Biopharma, Vanda Pharmaceuticals and China Unicom Hong Kong.

Four Must-See Charts: Biotech Stocks

Four Must-See Charts: Biotech Stocks

These biotech stocks could be setting up to make big moves.

Vanda Ripe for Picking, or Dead on the Vine?

Vanda Ripe for Picking, or Dead on the Vine?

A bull and a bear make their cases for whether a larger drug company will buy Vanda Pharmaceuticals.

Biotech Stock Mailbag: Oculus in Focus

Biotech Stock Mailbag: Oculus in Focus

Readers weigh in on Oculus Innovative Sciences, MAP Pharma, Human Genome and Hemispherx.

Hemispherx's CFS Drug Is a Long Shot

Hemispherx's CFS Drug Is a Long Shot

Too many red flags are flying over Hemispherx's chronic fatigue syndrome drug to be confident the FDA will approve it.

Tiny Biotechs Dancing in the Bull Pen

Tiny Biotechs Dancing in the Bull Pen

Itty bitty biotechs are big again, thanks to the H1N1 virus, cancer drug abstracts, and Vanda's recent success.

Biotech Stock Mailbag: Sequenom, Vanda

Readers want to know what's next for Sequenom after the data mishandling debacle, and what the prognosis is for Vanda.

Choppy Trading on More Stock Offerings

Choppy Trading on More Stock Offerings

Frank Curzio's guests include David Peltier, Adam Feuerstein, and Larsen Kusick.

Biotech Rocket Stocks for the Week

Biotech Rocket Stocks for the Week

These stocks could surge higher (or lower) in the coming days.

Vanda, Up 800%, Still Has Room to Rise

Vanda is up 800% after the FDA approved its schizophrenia drug Fanapt, but investors still may find reason to buy the stock.

Movers Roundup: Tenneco, Energy Conversion

Movers Roundup: Tenneco, Energy Conversion

Movers roundup: Tenneco jumps on upgrade, Energy Conversion sinks on plans to halt production

The Real Story, May 7

The Real Story, May 7

Frank Curzio's guests include Dan Fitzpatrick and Andrew Horowitz.

TheStreet Quant Rating: C (Hold)